Table 2.
Summary of the most commonly reported all-causality adverse events that occurred in more than two subjects in any treatment group
| No. of subjects with adverse eventa | No. of subjects (n = 48) with adverse event by treatment group: |
||
|---|---|---|---|
| Lersivirine (2,400 mg) | Moxifloxacin (400 mg) | Placebo | |
| Headache | 13 | 4 | 5 |
| Nausea | 11 | 0 | 0 |
| Vomiting | 5 | 0 | 0 |
| Diarrhea | 3 | 3 | 1 |
| Abdominal discomfort | 2 | 0 | 2 |
Shown are the Medical Dictionary for Regulatory Activities v12.1 preferred terms (19a).